CureVac NV
NASDAQ:CVAC
CureVac NV
Inventory
CureVac NV
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Inventory
€541k
|
CAGR 3-Years
-79%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Inventory
€110.7m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Inventory
€523.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Inventory
€11.8m
|
CAGR 3-Years
151%
|
CAGR 5-Years
118%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Inventory
€262k
|
CAGR 3-Years
8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-3%
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Inventory?
Inventory
541k
EUR
Based on the financial report for Dec 31, 2024, CureVac NV's Inventory amounts to 541k EUR.
What is CureVac NV's Inventory growth rate?
Inventory CAGR 5Y
-39%
Over the last year, the Inventory growth was -98%. The average annual Inventory growth rates for CureVac NV have been -79% over the past three years , -39% over the past five years .
